BrainsWay Reports 35% Revenue Surge and Raises 2026 Forecast After Strong Q2 Results

BrainsWay, a medical device company specializing in non-invasive deep brain magnetic stimulation for mental health disorders, reported record-breaking performance in the second quarter of 2026. The company, led by Hadar Levy, saw its revenues jump 35% year-over-year to a quarterly high of $17 million. Operating profit surged from approximately $600,000 to $2.4 million, with operating margin increasing from 5% to 14%. Adjusted EBITDA rose 141% to $3.5 million, and net profit grew 34% to $2.7 million.

Following these strong results, BrainsWay raised its full-year 2026 revenue guidance to a range of $68 million to $70 million, up from the previous forecast of $66 million to $68 million, representing up to 34% growth compared to 2025. The lower end of the adjusted EBITDA forecast was also increased from $12 million to $13 million, while the upper end remained at $14 million.

BrainsWay’s technology involves a helmet-like device delivering magnetic pulses to the brain, approved by the U.S. FDA for a shortened treatment course for major depressive disorder, including patients with anxiety symptoms. This accelerated treatment, lasting only a few days instead of weeks, has improved accessibility. The company also received approvals to treat younger patient groups.

After years of losses, BrainsWay turned profitable in Q4 2023 and has maintained positive net income since. 2024 marked its first full profitable year, with further improvements in 2025 and continued growth in early 2026. The company’s market value has soared from a low of 92 million shekels in May 2023 to approximately 1.8 billion shekels currently, reflecting strong investor confidence.

The company primarily operates in the U.S. and continues to expand its market presence and treatment offerings.